Cancer
Credibility 90
Efficacy and safety of darolutamide plus androgen-deprivation therapy in Black patients with metastatic hormone-sensitive prostate cancer from the phase 3 ARANOTE trial.
September 20, 2026 · Prostate cancer and prostatic diseases
Key takeaway
For Black men with advanced prostate cancer, this study found a new medicine, darolutamide, significantly slowed the cancer's spread when added to standard treatment. This is important because it offers our community another effective option to fight this disease.
Why this matters for our communities
Research in cancer helps close long-standing gaps in how Black and African American families are studied, diagnosed, and cared for. Use findings like this one to start informed conversations with your care team — not as a substitute for personal medical advice.
More in Cancer
February 1, 2027Dual-modal immunoassay for prostate cancer-derived exosomes enabled by a black phosphorus/silver SERS substrate and Yb/Er co-doped NaGdF4 UCL nanoprobes.Read December 18, 2026Factors Associated with Screening Mammography Utilization Among Women Veterans in VA Primary Care.Read November 16, 2026Characterizing prior symptomatic emergency department visits among patients undergoing unplanned colon cancer surgery.Read